Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 870-876

  Jung, Chan Kwon ^a   Kang, Won Kyung ^a   Park, Jae Myung ^a   Ahn, Hyo Jun ^a   Kim, Sang Woo ^a   Oh, Seong Taek ^a   Choi, Kyu Yong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Cannabinoid receptor; Kaplan meier analysis; Metastasis; Stage; Survival

Indexed keywords

CANNABINOID 1 RECEPTOR;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT OUTCOME;

EID: 84872704122     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1081     Document Type: Article

References (24)

1. Di Marzo V: Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7: 438-455, 2008.
2. Greenhough A, Patsos HA, Williams AC and Paraskeva C: The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer 121: 2172-2180, 2007.
3. Wang D, Wang H, Ning W, Backlund MG, Dey SK and DuBoisRN: Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68: 6468-6476, 2008.
4. Patsos HA, Hicks DJ, Dobson RR, et al: The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 54: 1741-1750, 2005.
5. Ligresti A, Bisogno T, Matias I, et al: Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125: 677-687, 2003.
6. Izzo AA and Camilleri M: Cannabinoids in intestinal inflammation and cancer. Pharmacol Res 60: 117-125, 2009.
7. Howlett AC, Barth F, Bonner TI, et al: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202, 2002.
8. Wright K, Rooney N, Feeney M, et al: Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129: 437-453, 2005.
9. Bedoya F, Rubio JC, Morales-Gutierrez C, et al: Single nucleotide change in the cannabinoid receptor-1 (CNR1) gene in colorectal cancer outcome. Oncology 76: 435-441, 2009.
10. Chung SC, Hammarsten P, Josefsson A, et al: A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 45: 174-182, 2009.
11. Michalski CW, Oti FE, Erkan M, et al: Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 122: 742-750, 2008.
12. Xu X, Liu Y, Huang S, et al: Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171: 31-38, 2006.
13. Gustafsson SB, Palmqvist R, Henriksson ML, et al: High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One 6: e23003, 2011.
14. Edge S, Byrd D, Compton C, Fritz A, Greene F and Trotti A: AJCC Cancer Staging Manual. Springer, New York, 2010.
15. Jass JR and Sobin LH (eds): Histological Typing of Intestinal Tumours. WHO International Histological Classification of Tumours. 2nd edition. Springer-Verlag, Berlin-New York, 1989.
16. Cianchi F, Papucci L, Schiavone N, et al: Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide denovo synthesis in colon cancer cells. Clin Cancer Res 14: 7691-7700, 2008.
17. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
18. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006.
19. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491-3494, 1998.
20. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E and KosmaVM: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318-324, 1997.
21. Massa F, Marsicano G, Hermann H, et al: The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202-1209, 2004.
22. Shaul YD and Seger R: The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 1773: 1213-1226, 2007.
23. Cudaback E, Marrs W, Moeller T and Stella N: The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS One 5: e8702, 2010.
24. Malfitano AM, Laezza C, Galgani M, et al: The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice. Pharmacol Res 65: 365-371, 2012.